| A646 |
Tislelizumab
Featured
|
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma. |
|
| A647 |
Concizumab
Featured
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia. |
|
| A648 |
NI-0701
Featured
|
|
|
| A649 |
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5)
Featured
|
|
|
| A650 |
Brigham and Women's patent anti-ABCB5
Featured
|
|
|
| A651 |
IgG1+Kappa Isotype Control
Featured
|
|
|
| A652 |
IgG4+Kappa Isotype Control
Featured
|
|
|
| A653 |
Prafnosbart
Featured
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research. |
|
| A654 |
Anti-ACVR2A Antibody (Ab-14E1)
Featured
|
|
|
| A655 |
Bimagrumab
Featured
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness. |
|
| A656 |
Acceleron patent anti-ActRIIB
Featured
|
|
|
| A657 |
IMGC-936
Featured
|
|
|
| A658 |
Enibarcimab
Featured
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research. |
|
| A659 |
Anti-AGER/RAGE Antibody (XT-M4)
Featured
|
|
|
| A660 |
Praluzatamab
Featured
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers. |
|
| A661 |
Anti-ALCAM/CD166 Antibody (AT002)
Featured
|
|
|
| A662 |
Seagen Patent Anti-Alpp
Featured
|
|
|
| A663 |
Prasinezumab
Featured
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research. |
|
| A664 |
Cinpanemab
Featured
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease. |
|
| A665 |
Murlentamab
Featured
|
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
|
| A666 |
Gantenerumab
Featured
|
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research. |
|
| A667 |
Crenezumab
Featured
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research. |
|
| A668 |
Donanemab
Featured
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. |
|
| A669 |
Solanezumab
Featured
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease. |
|
| A670 |
GSK-933776
Featured
|
|
|
| A671 |
Bapineuzumab
Featured
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD). |
|
| A672 |
Amgen patent anti-beta amyloid
Featured
|
|
|
| A673 |
Anti-Amyloid Beta Antibody (CNTO 2125)
Featured
|
|
|
| A674 |
Anti-Amyloid Beta Antibody (DLX212)
Featured
|
|
|
| A675 |
Georgetown U. patent anti-Amyloid Beta
Featured
|
|
|
